SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Pang Peter S.)
 

Sökning: WFRF:(Pang Peter S.) > (2010-2014) > Effect of Spironola...

Effect of Spironolactone on 30-Day Death and Heart Failure Rehospitalization (from the COACH Study)

Maisel, Alan (författare)
University of Calif San Diego, CA 92103 USA
Xue, Yang (författare)
University of Calif San Diego, CA 92103 USA
van Veldhuisen, Dirk J. (författare)
University of Groningen, Netherlands
visa fler...
Voors, Adriaan A. (författare)
University of Groningen, Netherlands
Jaarsma, Tiny (författare)
Linköpings universitet,Hälsa, Aktivitet, Vård (HAV),Hälsouniversitetet
Pang, Peter S. (författare)
Northwestern University, IL 60611 USA
Butler, Javed (författare)
Emory University, GA 30322 USA
Pitt, Bertram (författare)
University of Michigan, MI 48109 USA
Clopton, Paul (författare)
University of Calif San Diego, CA 92103 USA
de Boer, Rudolf A. (författare)
University of Groningen, Netherlands
visa färre...
 (creator_code:org_t)
Elsevier, 2014
2014
Engelska.
Ingår i: American Journal of Cardiology. - : Elsevier. - 0002-9149 .- 1879-1913. ; 114:5, s. 737-742
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • The aim of our study is to investigate the effect of spironolactone on 30-day outcomes in patients with acute heart failure (AHF) and the association between treatment and outcomes stratified by biomarkers. We conducted a secondary analysis of the biomarker substudy of the multicenter COACH (Co-ordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure) trial involving 534 AHF patients for 30-day mortality and HF rehospitalizations. Spironolactone therapy was initiated and terminated at the discretion of the treating physician; 30-day outcomes were compared between patients who were treated with spironolactone and those who were not. Outcomes with spironolactone therapy. were explored based on N-terminal pro-B-type natriuretic peptide, ST2, galectin-3, and creatinine levels. Spironolactone was prescribed to 297 (55.6%) patients at discharge (158 new and 139 continued). There were 19 deaths and 30 HF rehospitalizations among 46 patients by 30 days. Patients discharged on spironolactone had significantly less 30-day event (hazard ratio 0.538, p = 0.039) after adjustment for multiple risk factors. Initiation of spironolactone in patients who were not on spironolactone before admission was associated with a significant reduction in event rate (hazard ratio 0.362, p = 0.027). The survival benefit of spironolactone was more prominent in patient groups with elevations of creatinine, N-terminal pro B-type natriuretic peptide, ST2, or galectin-3. In conclusion, AHF patients who received spironolactone during hospitalization had significantly fewer 30-day mortality and HF rehospitalizations, especially in high-risk patients.

Ämnesord

SAMHÄLLSVETENSKAP  -- Sociologi (hsv//swe)
SOCIAL SCIENCES  -- Sociology (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy